Recombinant Tuberculosis BCG Vaccine Elicits a Highly Protective Host Immune Response

Tech ID: 20146 / UC Case 2006-538-0


UCLA researchers specializing in infectious diseases have developed an improved method for producing a recombinant tuberculosis (TB) vaccine that elicits a highly potent protective immune response in the host for preventing or treating TB in humans and in animals.


The only currently available TB vaccine, an attenuated Mycobacterium bovis strain Bacille Calmette-Guerin (BCG), is of variable efficacy. A large carefully conducted meta-analysis has estimated the potency of BCG to be approximately 50%. UCLA researchers developed and reported in the last several years a recombinant BCG expressing the Mycobacterium tuberculosis 30 kDa major secretory protein (r30). This vaccine, named rBCG30, induces greater protection than BCG against aerosol challenge with a highly virulent strain of M. tuberculosis.


UCLA researchers have developed an improved version of the rBCG30 vaccine that co-expresses host immunostimulatory molecules that shift the hosts immune response towards a more protective type of immune response. These vaccines are significantly more potent than the first generation rBCG30 vaccine in the highly relevant and stringent outbred guinea pig model of pulmonary tuberculosis, a model that closely mimics human tuberculosis.


A more potent and effective vaccine against TB.


  • Directs a hosts immune response towards a more potent protective immune response.
  • More efficacious than the currently available vaccine and even rBCG30, which itself is more potent than the currently available vaccine.

State of Development

This vaccine has been tested and proven effective in guinea pigs.

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 8,383,132 02/26/2013 2006-538
United States Of America Issued Patent 8,287,879 10/16/2012 2006-538


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Horwitz, Marcus A.

Other Information


therapeutics vaccine TB Tuberculosis treatment therapy

Categorized As